Antigen Pools for Melanoma via CLT Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly for cutaneous and uveal melanoma, lack effective antigen-specific immunotherapies due to limited identification of tumor-specific antigens, hindering the development of potent immune responses against cancer cells.
Innovation Solution
Development of antigen pools comprising cancer-specific LTR-element spanning transcripts (CLTs) and their encoded polypeptides, which are overexpressed in melanoma cells and presented on MHC molecules, eliciting specific immune responses by stimulating T-cells to target cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer therapies are used, then treatment is provided for melanoma, but effective antigen-specific immunotherapies are lacking due to limited identification of tumor-specific antigens
Solution Approach 1:
The patent segments the complex task of identifying tumor-specific antigens by focusing on a specific class of antigens (LTR-element spanning transcripts) and processing them through multiple stages: identification of CLTs, encoding of polypeptides, pooling of multiple antigens, and presentation on MHC molecules. This segmentation transforms an overwhelming problem into manageable steps, enabling systematic identification of effective antigens for melanoma immunotherapy.
Solution Approach 2:
The patent changes the parameter of antigen selection by shifting from conventional antigen identification methods to a novel approach based on LTR-element spanning transcripts. This parameter change involves identifying specific transcript types, encoding their polypeptides, and using these as immunogenic antigens, thereby transforming the limited antigen identification landscape into a more productive therapeutic approach.
2Adaptability or versatility
If antigen pools comprising CLTs are developed, then specific immune responses are elicited against melanoma cells, but complexity of antigen identification and pool composition increases
Solution Approach 1:
The patent creates universal antigen pools that can function across multiple contexts: they can stimulate various T-cell responses, target different melanoma cell types, and be used for both therapeutic and prophylactic purposes. The pooled antigens serve multiple functions simultaneously, reducing the need for separate antigen-specific treatments and simplifying the overall therapeutic approach despite the diversity of individual antigens.
Solution Approach 2:
The patent merges multiple individual CLT-encoded polypeptides into unified antigen pools. By combining several antigens that individually would require separate handling into integrated pools, the system achieves enhanced immune stimulation while reducing operational complexity. The merging process creates synergistic effects where the combination of antigens produces greater therapeutic benefit than individual components alone.
3Reliability
If T-cell populations reactive to CLT antigens are amplified, then potent immune responses are generated, but time and resources for ex vivo stimulation are increased
Solution Approach 1:
The patent performs preliminary action by pre-identifying and pre-pooling the optimal combination of CLT-encoded antigens before patient treatment. The antigen pools are prepared in advance with carefully selected antigens known to elicit strong T-cell responses. This preliminary preparation reduces the time required during actual treatment, as the stimulatory antigens are already optimized and ready for immediate use in ex vivo T-cell expansion without requiring lengthy screening processes.
Solution Approach 2:
The patent uses copying by creating standardized antigen pool formulations that can be replicated and used across multiple patients. Once an effective antigen pool composition is identified, it can be copied and produced batch-wise, reducing the time and resources required for each individual treatment. The copying approach allows for optimization in one instance to benefit subsequent treatments, accelerating the overall therapeutic process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antigen pools induce strong, specific immune responses against melanoma cells, enabling therapeutic or prophylactic immunotherapy by amplifying T-cell populations reactive to CLT antigens, potentially leading to improved treatment outcomes for melanoma patients.
Implementation Method 1
cancer-specific LTR-element spanning transcripts (CLTs) and their encoded polypeptides, which are overexpressed in melanoma cells and presented on MHC molecules
Implementation Method 2
eliciting specific immune responses by stimulating T-cells to target cancer cells
Data Source
AI summary
There are disclosed inter alia antigen pools which are useful in the treatment of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.